ES2532896T3 - Péptidos del HMC de clase II novedosos y potentes derivados de survivina y neurocan - Google Patents

Péptidos del HMC de clase II novedosos y potentes derivados de survivina y neurocan Download PDF

Info

Publication number
ES2532896T3
ES2532896T3 ES08008944.4T ES08008944T ES2532896T3 ES 2532896 T3 ES2532896 T3 ES 2532896T3 ES 08008944 T ES08008944 T ES 08008944T ES 2532896 T3 ES2532896 T3 ES 2532896T3
Authority
ES
Spain
Prior art keywords
neurocan
survivin
potent
novel
peptides derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08008944.4T
Other languages
English (en)
Other versions
ES2532896T5 (es
Inventor
Hans-Georg Prof. Dr. Rammensee
Stefan Prof. Dr. Stevanovic
Cécile Dr. Gouttefanges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39789337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2532896(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Application granted granted Critical
Publication of ES2532896T3 publication Critical patent/ES2532896T3/es
Publication of ES2532896T5 publication Critical patent/ES2532896T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Péptido consistente en la secuencia de aminoácidos de la SEC ID N.º 1 (TLGEFLKLDRERAKN).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
Tabla 2: Los 30 alelos más expresados en diversas poblaciones
Probabilidad de que un alelo se exprese en un individuo (%)
Los 30 alelos más expresados
Alelo
Caucásicos Alelo Afroamericanos Alelo Hispanos Alelo Oriental
A*0201
45,6% C*0401 29,0% A*0201 37,1% A*1101 38,4%
C*0701
27,7% C*0701 25,4% C*0401 25,4% A*2402 33,7%
A*0101
27,4% C*0602 23,0% A*2402 24,9% C*0702 33,3%
A*0301
23,8% A*0201 22,3% C*0702 24,2% C*0102 27,7%
C*0702
21,5% A*2301 20,7% C*0701 20,8% A*3303 23,3%
C*0401
21,2% C*0202 19,0% C*0304 14,4% C*0801 21,6%
B*4402
20,2% A*0301 18,7% A*0301 14,3% C*0304 19,9%
B*0702
18,1% C*0702 18,1% B*0702 13,2% A*0201 18,1%
B*0801
18,1% B*5301 18,1% B*3501 12,8% B*4001 15,2%
C*0501
17,2% B*0702 15,8% C*0602 12,3% C*0401 14,0%
C*0304
16,8% C*1601 15,7% C*0501 11,9% B*5801 13,3%
C*0602
15,7% B*1503 13,9% A*0101 11,4% B*4601 12,7%
A*1101
15,3% B*5801 13,5% A*1101 11,0% B*5101 12,4%
B*4001
13,6% A*6802 12,7% B*5101 10,8% C*0302 12,0%
A*2402
12,1% C*1701 11,7% C*1601 10,6% B*3802 11,4%
B*3501
10,7% B*4501 10,8% B*4403 9,9% A*0207 11,0%
C*0303
10,6% B*4201 10,5% C*0102 9,7% B*1501 9,4%
B*5101
10,4% A*3001 10,4% A*2902 9,7% A*0206 9,3%
C*1203
9,9% B*3501 10,1% C*0802 9,3% C*0303 9,2%
B*1501
9,6% A*0101 10,0% B*1801 9,1% B*1502 9,1%
A*2902
8,9% C*0304 9,3% A*3101 8,9% A*0203 8,8%
A*2601
8,2% A*3002 9,2% B*5201 8,6% B*4403 8,6%
A*3201
8,2% B*0801 8,5% B*1402 8,6% C*1402 8,4%
C*0802
7,7% A*3402 8,4% C*0202 7,6% B*3501 7,2%
A*2501
7,5% A*7401 8,4% C*1203 7,6% C*0602 7,0%
B*5701
7,1% A*3303 8,0% A*2601 7,6% B*5401 6,9%
B*1402
6,7% C*1801 7,3% A*6801 7,1% B*1301 6,6%
C*0202
6,6% A*2902 7,2% B*0801 7,0% B*4002 6,3%
B*1801
6,4% B*4403 6,9% A*3002 6,8% B*5502 6,3%
B*4403
6,4% B*4901 6,9% B*4402 6,5% A*2601 6,0%
Tres locus diferentes del genoma humano albergan los genes MHC de clase II: HLA-DR, HLA-DQ y HLA-DP. Los receptores MHC de clase II son heterodímeros que constan de una cadena alfa y una beta, las cuales se insertan en 5 la membrana celular a través de una región transmembranosa. HLA-DRB1*04 y HLA-DRB1*07 son dos ejemplos de alelos MHC de clase II beta que se sabe que están codificados en estos locus. Los alelos de clase II son muy polimorfos: por ejemplo, se han descrito varios cientos de alelos HLA-DRB1 distintos. Por tanto, a efectos terapéuticos y de diagnóstico sería muy deseable contar con un péptido que se una, con la afinidad adecuada, a varios receptores HLA de clase II distintos. Un péptido que se une a varias moléculas HLA de clase II distintas recibe
10 el nombre de ligando promiscuo.
En la presente memoria, la referencia a una secuencia de ADN incluye tanto ADN monocatenario como bicatenario. Por lo tanto, la secuencia específica, a menos que el contexto indique otra cosa, se refiere al ADN monocatenario de dicha secuencia, a la doble cadena formada por dicha secuencia con su complementaria (ADN bicatenario) y a la cadena complementaria de dicha secuencia. El término "región codificante" hace referencia a la porción de un gen
15 que, o bien de forma natural o normal, codifica el producto de expresión de dicho gen en su ambiente genómico natural, por ejemplo, la región que codifica in vivo el producto de expresión natural del gen.
La región codificante puede formar parte de un gen normal, mutado o alterado, o incluso puede provenir de una secuencia de ADN, o gen, sintetizada íntegramente en el laboratorio con métodos bien conocidos por los expertos en la síntesis de ADN.
20 El término "secuencia nucleotídica" hace referencia a un heteropolímero de desoxirribonucleótidos.
La secuencia nucleotídica que codifica un péptido, oligopéptido o polipéptido en particular puede ser natural o estar construida de forma sintética. Generalmente, los segmentos de ADN que codifican los péptidos, polipéptidos y proteínas de la presente invención se ensamblan a partir de fragmentos de ADNc y de oligonucleótidos cortos de enlace, o a partir de una serie de oligonucleótidos, con el fin de proporcionar un gen sintético capaz de ser 25 expresado en una unidad transcripcional recombinante que comprenda elementos reguladores derivados de un
7
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42

Claims (1)

  1. imagen1
ES08008944.4T 2008-05-14 2008-05-14 Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan Active ES2532896T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08008944.4A EP2119726B2 (en) 2008-05-14 2008-05-14 Novel and powerful MHC-class II peptides derived from survivin and neurocan

Publications (2)

Publication Number Publication Date
ES2532896T3 true ES2532896T3 (es) 2015-04-01
ES2532896T5 ES2532896T5 (es) 2018-03-20

Family

ID=39789337

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08008944.4T Active ES2532896T5 (es) 2008-05-14 2008-05-14 Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
ES09745570T Active ES2549088T5 (es) 2008-05-14 2009-05-14 Nuevos y potentes péptidos del MHC de clase II derivados de la survivina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09745570T Active ES2549088T5 (es) 2008-05-14 2009-05-14 Nuevos y potentes péptidos del MHC de clase II derivados de la survivina

Country Status (24)

Country Link
US (5) US8647629B2 (es)
EP (3) EP2119726B2 (es)
JP (1) JP5663473B2 (es)
KR (2) KR101509284B1 (es)
CN (1) CN102027006B (es)
AU (1) AU2009248413B2 (es)
BR (2) BRPI0912622A2 (es)
CA (1) CA2724198C (es)
CY (2) CY1115999T1 (es)
DK (2) DK2119726T5 (es)
EA (1) EA019603B1 (es)
ES (2) ES2532896T5 (es)
HK (1) HK1209757A1 (es)
HR (2) HRP20151135T4 (es)
HU (2) HUE024541T2 (es)
MX (1) MX2010012443A (es)
NO (1) NO2119726T3 (es)
NZ (1) NZ588605A (es)
PL (2) PL2119726T5 (es)
PT (2) PT2119726E (es)
RS (1) RS53872B2 (es)
SI (2) SI2119726T2 (es)
UA (1) UA103481C2 (es)
WO (1) WO2009138236A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
BRPI0814140A2 (pt) * 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
HUE054585T2 (hu) 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
DE602008000891D1 (de) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012023033A2 (en) * 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
SG191154A1 (en) * 2010-12-14 2013-07-31 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN102181401B (zh) * 2011-02-01 2013-04-24 北京市肿瘤防治研究所 存活素酶联免疫试剂盒及其应用
IN2014CH00391A (es) * 2013-02-05 2015-04-03 Nitto Denko Corp
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
WO2015066057A2 (en) * 2013-10-28 2015-05-07 Baylor College Of Medicine Expansion of cmv-specific t cells from cmv-seronegative donors
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
ES2947818T3 (es) 2014-11-18 2023-08-21 Ascendis Pharma Endocrinology Div A/S Nuevos profármacos poliméricos de la HCh
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3273986T3 (fi) * 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3919507A3 (en) * 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CR20170579A (es) * 2015-07-06 2018-05-25 Immatics Biotechnologies Gmbh Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MY198087A (en) * 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
PT3429618T (pt) 2016-03-16 2024-04-02 Amal Therapeutics Sa Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
EP3475706B1 (en) * 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
KR20190037243A (ko) * 2016-06-28 2019-04-05 지니우스 바이오테크놀로지 인코포레이티드 면역치료를 위한 티 세포 조성물
IL265479B (en) 2016-09-21 2022-09-01 Amal Therapeutics Sa A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
PE20191248A1 (es) 2017-01-27 2019-09-18 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
AU2018226566B2 (en) 2017-03-03 2025-01-23 Treos Bio Limited Population-based immunogenic peptide identification platform
CN119080881A (zh) * 2017-07-07 2024-12-06 伊玛提克斯生物技术有限公司 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
WO2019007974A1 (en) * 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
JP7232825B2 (ja) 2017-10-09 2023-03-03 エンテローム エスエー 腫瘍関連抗原エピトープの微生物叢（ｍｉｃｒｏｂｉｏｔａ）配列変異体
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
CA3100072A1 (en) 2018-05-15 2019-11-21 Interk Peptide Therapeutics Limited Activating agents
EP3794014A4 (en) * 2018-05-15 2022-03-16 InterK Peptide Therapeutics Limited PEPTIDE ACTIVATING AGENT
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
EP3934625A1 (en) 2019-03-04 2022-01-12 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
LT4021487T (lt) 2019-11-15 2024-02-12 Enterome S.A. Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui
CN113045635B (zh) * 2019-12-26 2025-12-16 上海细胞治疗集团股份有限公司 一种特异性结合hla-a2分型的多肽组合物及应用
IL296881A (en) * 2020-04-14 2022-12-01 Universit? De Montr?Al New antigens specific for acute myeloid leukemia (aml) and their uses
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
JP7661734B2 (ja) * 2021-03-19 2025-04-15 日本電気株式会社 検査システム及び検査方法
IL316712B2 (en) * 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
CA3229551A1 (en) * 2021-08-17 2023-02-23 Intomics A/S Vaccine design pipeline
CN119522232A (zh) 2022-03-31 2025-02-25 恩特姆生物科学公司 用于预防和治疗癌症的抗原肽
WO2026067858A1 (zh) * 2024-09-30 2026-04-02 康希诺(上海)生物研发有限公司 一种用于免疫/治疗肿瘤的组合物及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6255055B1 (en) 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US6274362B1 (en) 1999-02-04 2001-08-14 Millennium Pharmaceuticals, Inc. RGS-containing molecules and uses thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003051051A1 (en) 2001-12-13 2003-06-19 Koninklijke Philips Electronics N.V. Recommending media content on a media system
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20040180354A1 (en) * 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
US7468254B2 (en) 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US8435507B2 (en) * 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
EP1806358B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
AU2006311538A1 (en) † 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
BRPI0814140A2 (pt) * 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
DE602008000891D1 (de) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
RS53872B2 (sr) * 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera

Also Published As

Publication number Publication date
SI2291395T2 (sl) 2019-03-29
RS53872B2 (sr) 2018-06-29
JP5663473B2 (ja) 2015-02-04
EP2291395B2 (en) 2018-11-14
DK2291395T4 (en) 2019-02-18
US8647629B2 (en) 2014-02-11
US20100029571A1 (en) 2010-02-04
PT2291395E (pt) 2015-10-23
CN102027006A (zh) 2011-04-20
US11957729B2 (en) 2024-04-16
EP2119726A1 (en) 2009-11-18
SI2119726T1 (sl) 2015-05-29
ES2532896T5 (es) 2018-03-20
HRP20150300T4 (hr) 2018-03-09
JP2011520436A (ja) 2011-07-21
US20200078439A1 (en) 2020-03-12
PL2119726T5 (pl) 2018-04-30
PT2119726E (pt) 2015-03-30
HRP20151135T1 (hr) 2015-11-20
BRPI0912622A2 (pt) 2016-05-03
BR122019014468B8 (pt) 2021-07-27
WO2009138236A1 (en) 2009-11-19
KR101509284B1 (ko) 2015-04-10
RS53872B1 (sr) 2015-08-31
SI2291395T1 (sl) 2015-10-30
DK2119726T4 (en) 2018-02-19
US20130323272A1 (en) 2013-12-05
BR122019014468B1 (pt) 2020-09-15
PL2119726T3 (pl) 2015-05-29
DK2291395T3 (da) 2015-09-21
KR20130041375A (ko) 2013-04-24
EP2899206A1 (en) 2015-07-29
PL2291395T5 (pl) 2019-04-30
CA2724198C (en) 2016-03-22
KR101602024B1 (ko) 2016-03-09
KR20110021881A (ko) 2011-03-04
UA103481C2 (ru) 2013-10-25
CY1115999T1 (el) 2017-01-25
MX2010012443A (es) 2010-12-20
US10434136B2 (en) 2019-10-08
CA2724198A1 (en) 2009-11-19
US20140127242A1 (en) 2014-05-08
EP2119726B2 (en) 2017-11-29
SI2119726T2 (en) 2018-03-30
EA201071297A1 (ru) 2011-04-29
HRP20150300T1 (hr) 2015-04-24
DK2119726T5 (en) 2018-03-26
CY1117171T1 (el) 2017-04-05
EP2119726B1 (en) 2014-12-24
US9498512B2 (en) 2016-11-22
HK1156323A1 (en) 2012-06-08
HUE024541T2 (hu) 2016-01-28
CN102027006B (zh) 2016-01-13
HK1209757A1 (en) 2016-04-08
ES2549088T3 (es) 2015-10-22
DK2119726T3 (en) 2015-02-16
EA019603B1 (ru) 2014-04-30
NZ588605A (en) 2012-06-29
ES2549088T5 (es) 2019-04-29
EP2291395B1 (en) 2015-08-12
HUE028102T2 (en) 2016-11-28
AU2009248413A1 (en) 2009-11-19
EP2291395A1 (en) 2011-03-09
HRP20151135T4 (hr) 2019-03-08
PL2291395T3 (pl) 2016-01-29
US20140086943A1 (en) 2014-03-27
NO2119726T3 (es) 2015-05-23
AU2009248413B2 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
Keestra et al. Unique features of chicken Toll-like receptors
Chappell et al. Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding
Ting et al. Genetic control of MHC class II expression
Brockton et al. Gene characterisation, isoforms and recombinant expression of carcinin, an antibacterial protein from the shore crab, Carcinus maenas
Kowalski et al. Linker histone subtypes and their allelic variants
Rogers et al. Characterization of new members of the human type II keratin gene family and a general evaluation of the keratin gene domain on chromosome 12q13. 13
Mykles et al. Cloning of tropomyosins from lobster (Homarus americanus) striated muscles: fast and slow isoforms may be generated from the same transcript
CA2880331A1 (en) Method for identifying novel minor histocompatibility antigens
RU2020123735A (ru) Способ лечения рака
JP7809381B2 (ja) 卵巣がんに対する新規の腫瘍特異的抗原およびそれらの使用
Osuna-Jimenez et al. Immune-and stress-related transcriptomic responses of Solea senegalensis stimulated with lipopolysaccharide and copper sulphate using heterologous cDNA microarrays
CN110195059B (zh) 核酸分子、表达载体及应用、抗菌药物和方法
Janda et al. Plectin repeats and modules: strategic cysteines and their presumed impact on cytolinker functions
Cuc et al. Multiple maternal lineages of Vietnamese local chickens inferred by mitochondrial DNA D-loop sequences
Caulier et al. The CCR4–NOT complex: a multifaceted sensor of molecular signals instructing eukaryotic mRNA translation and stability
Kollmar et al. Identification and phylogenetic analysis of Dictyostelium discoideum kinesin proteins
Cao et al. MHC class IIα polymorphism and its association with resistance/susceptibility to Vibrio harveyi in golden pompano (Trachinotus ovatus)
Yang et al. Association between genetic polymorphism in the swine leukocyte antigen-DRA gene and piglet diarrhea in three Chinese pig breeds
Michel et al. Diversity and evolution of MHII β genes in a non-model percid species—the Eurasian perch (Perca fluviatilis L.)
CN115697373A (zh) 线粒体衍生肽和其类似物作为包括癌症的年龄相关性疾病的治疗的用途
Padovan et al. Histatins in non-human primates: gene variations and functional effects
US10414813B2 (en) Minor histocompatibility antigens and uses thereof
WO2022196699A1 (ja) ＳＡＲＳ－ＣｏＶ－２ウイルスに特異的な濾胞性ヘルパーＴ細胞（Ｔｆｈ）
Friedberg et al. Multiple calmodulin genes in fish
Nelson et al. The complete mitochondrial genome of the gall-forming fly, Fergusonina taylori Nelson and Yeates (Diptera: Fergusoninidae)